Tevogen Bio Holdings Stock (NASDAQ: TVGN)

Dernières nouvelles pour Tevogen Bio Holdings (NASDAQ:TVGN) Stock

Tevogen Bio Holdings

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Tevogen Bio Holdings Inc

With the Dow Jones Industrial Average at all-time highs, the earnings report from UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) on Tuesday before the market open could be <a href="https://www.benzinga.com/earnings">of particular interest.</a>
Earnings Estimates: Analysts expect UnitedHealth to report third-quarter revenue of $99.28 billion, up from $92.36 billion in last year's third quarter, according to data<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101424&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a>
The company has beaten analyst estimates for revenue in nine of the last 10 quarters, with the most recently <a href="https://www.benzinga.com/news/earnings/24/07/39790051/unitedhealth-q2-earnings-revenue-and-eps-beat-lifts-cyberattack-impact-estimate-reaffirms-profit-ou">reported second-quarter</a> results the lone miss.
Analysts expect the company to report third-quarter earnings per share of $7.00, up from $6.56 in last year's third quarter. The company has beaten analyst estimates for earnings per share in nine of the last 10 quarters, with the lone miss coming in the second quarter.
Read Also: <a href="https://www.benzinga.com/news/large-cap/24/10/41256923/cvs-unitedhealth-request-ftc-chair-recusal-amid-ongoing-pharmacy-benefit-managers-lawsuit">CVS, UnitedHealth Request FTC Chair Recusal Amid Ongoing Pharmacy Benefit Managers Lawsuit</a>
Why It's Important: UnitedHealth's second quarter results were significantly impacted by a cyberattack against the company's billing and payments business, which led to misses in earnings and revenue compared to analyst estimates.
Third-quarter estimates expect the company to post growth on a year-over-year basis for both segments and the stock could be one of the most watched for the week with earnings season in full swing.
With a share price over $600, UnitedHealth is currently the largest weighting in the price-weighted Dow Jones Industrial Average at around 9.5%.
"Look for United Healthcare to move markets as it is the largest component in the Dow Jones Industrial Average," Freedom Capital Markets Chief Global Strategist Jay Woods said in his weekly <a href="https://jaywoods.substack.com/">newsletter</a>. &nbsp;
The earnings report comes with the Dow Jones Industrial Average<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41319060/s-p-500-extends-record-highs-dow-breaks-43-000-ahead-of-pivotal-earnings-week-bitco"> hitting new all-time highs </a>of 43,111.45 on Monday. The SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), which tracks the index, was up 0.5% to $430.89 on Monday.
Recent<a href="https://www.benzinga.com/quote/UNH/analyst-ratings"> analyst ratings for </a>UnitedHealth include Cantor Fitzgerald reiterating an Overweight rating with a $591 price target and KeyBanc initiating the stock with an Overweight rating with a $675 price target.
UNH Price Action: UnitedHealth stock was up 1.2% to $605.40 on Monday, versus a 52-week trading range of $436.38 to $607.90. UnitedHealth stock is up 12.5% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/24/09/40965040/unitedhealth-vs-cvs-vs-cigna-which-health-stock-will-beat-the-ftcs-regulatory-heat">UnitedHealth Vs. CVS Vs. Cigna: Which Health Stock Will Beat The FTC&#8217;s Regulatory Heat?</a></li>
</ul>
Photo: JHVEPhoto/Shutterstock.com

Previews

Trading Ideas

SPDR Dow Jones Industrial Average ETF Trust

UnitedHealth Group Q3 Earnings Preview: Dow Jones Industrial Average Stock Could 'Move Markets' Tuesday

News

Management

JYNT

The Joint Corp Appoints Sanjiv Razdan As Its President And CEO, Effective Today; Peter Holt Resigns

September production decreased by approximately&nbsp;2%&nbsp;month over month from August (19.7 BTC mined) due to the increase in the bitcoin difficulty level which peaked at 92.67 in September vs. 90.67 in August 2024.
&nbsp;

GRYP

Gryphon Digital Mining Releases Operational Update For September; Expect To Have Generated Revenues Of $1.16M For September, Based On An Average Bitcoin Price Of $60,286

Investors interested in Furniture stocks are likely familiar with Flexsteel Industries (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flxs#NASDAQ">FLXS</a>) and SharkNinja, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sn#NYSE">SN</a>). But which of these two stocks presents investors with the better value opportunity right now? Let&#39;s take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Flexsteel Industries and SharkNinja, Inc. are both sporting a Zacks Rank of # 1 (Strong Buy) right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that both of these companies have improving earnings outlooks. But this is just one piece of the puzzle for value investors.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
FLXS currently has a forward P/E ratio of 13.79, while SN has a forward P/E of 25.42. We also note that FLXS has a PEG ratio of 1.15. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company&#39;s expected earnings growth rate. SN currently has a PEG ratio of 1.72.
Another notable valuation metric for FLXS is its P/B ratio of 1.42. Investors use the P/B ratio to look at a stock&#39;s market value versus its book value, which is defined as total assets minus total liabilities. By comparison, SN has a P/B of 9.12.
Based on these metrics and many more, FLXS holds a Value grade of A, while SN has a Value grade of D.
Both FLXS and SN are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that FLXS is the superior value option right now.
<a href="https://www.zacks.com/stock/news/2350085/flxs-or-sn-which-is-the-better-value-stock-right-now?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_3-2350085">To read this article on Zacks.com click here.</a>

Earnings

Large Cap

Small Cap

Markets

Analyst Ratings

Tech

FLXS

FLXS or SN: Which Is the Better Value Stock Right Now?

SGHT

Sight Sciences Reports Publication Of New Study Titled, Impact Of TearCare On Reading Speed In Patients With Dry Eye Disease In The Peer-reviewed Journal Clinical Ophthalmology

WIIM

PHX Minerals shares are trading higher after the company announced WhiteHawk Energy sent a letter regarding its acquisition proposal.

Blink is offering a solution for former Enel X and JuiceBox customers to power up their EV charging with Blink.&nbsp;
All customers need to do is prepare their site, and Blink will handle the rest. Additionally, if you already have a JuiceBox charging station but need an upgrade, Blink will swap it out for free.

BLNK

Blink Charging Steps In To Support EV Charging Station Hosts Affected By Enel X's Recent Decision To Close Its North American Operations

Investors interested in stocks from the Financial - Investment Management sector have probably already heard of Victory Capital Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vctr#NASDAQ">VCTR</a>) and SEI Investments (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/seic#NASDAQ">SEIC</a>). But which of these two stocks offers value investors a better bang for their buck right now? We&#39;ll need to take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Victory Capital Holdings and SEI Investments are both sporting a Zacks Rank of # 2 (Buy) right now. Investors should feel comfortable knowing that both of these stocks have an improving earnings outlook since the Zacks Rank favors companies that have witnessed positive analyst estimate revisions. However, value investors will care about much more than just this.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
VCTR currently has a forward P/E ratio of 11.12, while SEIC has a forward P/E of 16.52. We also note that VCTR has a PEG ratio of 0.61. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company&#39;s expected earnings growth rate. SEIC currently has a PEG ratio of 1.38.
Another notable valuation metric for VCTR is its P/B ratio of 3.36. The P/B ratio pits a stock&#39;s market value against its book value, which is defined as total assets minus total liabilities. For comparison, SEIC has a P/B of 4.05.
These metrics, and several others, help VCTR earn a Value grade of B, while SEIC has been given a Value grade of C.
Both VCTR and SEIC are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that VCTR is the superior value option right now.
<a href="https://www.zacks.com/stock/news/2350084/vctr-vs-seic-which-stock-is-the-better-value-option?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_3-2350084">To read this article on Zacks.com click here.</a>

Mid Cap

SEIC

VCTR

VCTR vs. SEIC: Which Stock Is the Better Value Option?

Sphere Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) and the Department of Culture and Tourism – Abu Dhabi announced that they will work together to bring the world's second Sphere to Abu Dhabi, United Arab Emirates. This next-generation entertainment medium is expected to be a landmark addition to this premier international capital city, elevating the entertainment offerings for residents and visitors alike.

Global

SPHR

Sphere Entertainment And The Department Of Culture And Tourism – Abu Dhabi Announce Plans To Make Abu Dhabi Next Sphere Venue Location

MDAI

Spectral AI shares are trading higher after the company announced it named its founder Dr. J. Michael DiMaio as the Chairman.

Spectral AI Names Founder Dr. J. Michael DiMaio As Chairman

<a href="https://pr.report/3i0a">Gryphon Digital Mining</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) ("Gryphon" or the "Company"), a bitcoin mining company that is focused on low-cost, efficient operations, has released its unaudited operational update for September 2024.
Key September 2024 highlights:
Steve Gutterman Named as Chief Executive Officer, Jimmy Vaipoulos as Chairman and Sim Salzman to continue as Chief Financial Officer
+500 MW power pipeline: Gryphon continues to evaluate a pipeline of similar low-cost opportunities for potentially +500 MW
Improved Hashrate: Monthly average hashrate of 920 PH/s, a 4% increase over August 2024
Bitcoin Production: Expect to have produced approximately 19.31 bitcoin
Projected approximately $1.16 million in value based on an average bitcoin price for the month of $60,286
High Uptime: 98.7% mining fleet average up time in September following 97.3% in August due to maintenance
Sustainable Operations: Scope 1 and Scope 21 operations at our Northeastern U.S. operations continue to be 100% electrified by zero-carbon emitting hydro power

Gryphon Digital Mining Announces September Operational Update; Expect To Have Produced ~19.31 Bitcoin

The letter includes details of the extensive efforts WhiteHawk has made over the past 18 months to engage with PHX to maximize value for stockholders through a transaction.
Urges the PHX Board of Directors to engage with WhiteHawk to pursue and complete a transaction following unwillingness to engage over the past 18 months

WhiteHawk Energy Sends Letter To PHX Minerals Chairman Mark Behrman With Respect To Its $4.00 Per Share Proposal

<a href="https://patentcenter.uspto.gov/applications/17677698/ifw/docs" title="https://patentcenter.uspto.gov/applications/17677698/ifw/docs">https://patentcenter.uspto.gov/applications/17677698/ifw/docs</a>

Biotech

General

HOTH

Hoth Therapeutics Has Received A Notice Of Allowance For Its U.S. Patent Application 17/677,698 Titled "USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE".

Former Congressman Joe Garcia, who represented Florida's 26th congressional district, has voiced strong support for the cannabis legalization measure, known as <a href="https://www.benzinga.com/markets/cannabis/24/04/38034138/florida-supreme-court-approves-cannabis-legalization-proposal-for-november-election-in-blow-to-d" target="_blank" rel="noreferrer noopener">Amendment 3</a>, that will appear on the ballot in the <a href="https://www.benzinga.com/topic/2024-election">upcoming November elections</a>
"One of the most compelling reasons to support Amendment 3 is the growing body of research that suggests marijuana acts as an exit substance, not a gateway drug," said Garcia in a <a href="https://www.miamiherald.com/opinion/article293689854.html">Miami Herald</a> opinion piece. "Contrary to outdated beliefs, numerous studies have shown that marijuana can help individuals reduce their dependence on more harmful substances, including prescription opioids."
He pointed out that the illicit market poses risks, including reports of marijuana being laced with dangerous substances like <a href="https://www.benzinga.com/topic/fentanyl">fentanyl</a>. By regulating the market, Florida could ensure that consumers have access to safe, lab-tested products, he said.
Garcia also addressed concerns about teenage cannabis use. "Research indicates that in states where marijuana is legal, teen use rates have actually declined. This is likely due to the stringent regulations and safeguards that come with legalization, making it more difficult for underage individuals to access marijuana."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41250277/miami-herald-endorses-florida-cannabis-legalization-highlights-failed-drug-war-revenue-potential">Miami Herald Endorses Florida Cannabis Legalization, Highlights Failed Drug War, Revenue Potential</a>
<h2 class="wp-block-heading">And Then There's The Money</h2>
Estimates suggest that legalized marijuana could generate up to $431 million annually in new tax revenue in Florida.
"This influx of funds could be directed toward essential public services such as education, healthcare and infrastructure. Imagine the positive impact on our schools, hospitals and roads with this additional revenue stream. It's an opportunity to invest in our future and improve the quality of life for all Floridians," Garcia wrote.
This new source of income, he said, could have a transformative impact on the state.
"We have fewer individual freedoms and we are passing up millions in tax revenue, tourism dollars and market growth that will create new jobs right here in Florida. Amendment 3 is not just about legalizing marijuana; it's about adopting a sensible, evidence-based approach to drug policy."
Garcia is a paid advisor for the organization <a href="https://drupal-cloudfront.benzinga.com/topic/smart-and-safe-florida" target="_blank" rel="noreferrer noopener">Smart and Safe Florida</a>, which helped get Amendment 3 on the ballot.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41303141/fact-check-desantis-why-floridas-weed-legalization-does-not-mean-smoking-in-schools">Fact-Check DeSantis: Why Florida&#8217;s Weed Legalization Does Not Mean Smoking In Schools</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Cannabis

Regulations

Politics

Legal

Florida Cannabis Legalization Gains Support From Former Congressman, Citing Economic Growth, Public Health

Editor&#8217;s note: This article was updated to correctly state the title of the CCO and co-founder of Cornbread Hemp.
A California judge has denied a temporary restraining order (TRO) filed by national hemp advocates and businesses, including <a href="https://www.benzinga.com/markets/cannabis/24/10/41196739/cheech-and-chong-cannabis-company-hemp-roundtable-petition-court-to-stop-gov-newsoms-controversi">Cheech and Chong's Global Holdings</a>, aimed at blocking the state's controversial ban on hemp products with detectable levels of THC. 
The TRO, which was requested as part of a lawsuit filed last month by the U.S. Hemp Roundtable and several hemp companies, sought to halt the enforcement of the new regulations until the case could be fully heard. 
However, the judge sided with the state and Gov. Gavin Newsom, allowing the ban to remain in place.
<h3 class="wp-block-heading">Emergency Regulations Banning Hemp</h3>
The <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">emergency regulations</a>, which went into effect on September 23, prohibit the sale of consumable hemp products with any detectable delta-9 THC or intoxicating cannabinoids like delta-8 THC in California. 
These regulations also limit hemp products to five servings per package and restrict sales to individuals aged 21 and over. 
Hemp advocates argue that this will severely impact the industry, especially businesses producing non-intoxicating hemp products that provide therapeutic benefits to consumers.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41124583/californias-new-hemp-rules-could-reshape-cannabis-a-different-set-of-rules-in-every-state">California&#8217;s New Hemp Rules Could Reshape Cannabis: &#8216;A Different Set Of Rules In Every State&#8217;</a>
<h3 class="wp-block-heading">Industry Reacts</h3>
The ruling prompted strong reactions. 
&#8220;Today, a judge sided against common sense and in favor of Gov. Newsom. The judge's ruling to deny a temporary restraining order against Newsom's hemp products ban announces that Californians will lose access to USDA-certified organic hemp products in retail stores across the state,&#8221; Jim Higdon, CCO and co-founder of <a href="https://www.benzinga.com/markets/cannabis/24/09/40833963/expert-calls-for-a-united-hemp-and-cannabis-front-industries-should-collaborate-and-push-for-fed">Cornbread Hemp </a>and a member of the U.S. Hemp Roundtable, told Benzinga Cannabis in an email.
&#8220;At a time when the California cannabis dispensary system is undergoing a credibility crisis due to pesticide contamination, the governor has made it much more difficult for Californians to access the only cannabis products that consumers can be certain are free of pesticides – USDA-certified organic hemp products with third-party lab tests,&#8221; Higdon said.
The legal battle is set to continue, as the case moves forward, with the hemp industry determined to challenge the ban's legality in court.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">Gov. Newsom&#8217;s Hemp Ban Goes Into Effect: Consequences For Industry, Investors, Patients</a></li>
</ul>
Cover: AI Generated Image

Government

California Judge Rules Gov. Newsom's Hemp Ban Stands Despite Industry Pushback (Corrected)

HubSpot, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hubs#NYSE">HUBS</a>) recently inked a definitive agreement to acquire Cacheflow, an industry leader in B2B subscription billing management and configure, price, quote (CPQ) solution, for an undisclosed amount. Cacheflow will operate as HUBS&#39; wholly owned subsidiary following the completion of the buyout.
Cascheflow&#39;s AI native billing and subscription management solution is designed to streamline software buying and selling processes in a B2B space. The solution provides a unified, no-code platform for automating the SaaS sales flow.
In 2023, HubSpot introduced Commerce Hubs&#39; on its smart CRM (Customer Relationship Management) to simplify various processes such as invoicing and payments. HUBS&#39; Commerce Hub offering has gained solid market traction over the past year. With this acquisition, the company is aiming to further strengthen Commerce Hubs&#39; functionalities and enhance its prospects across industries.
Cacheflow&#39;s portfolio will make the quote-to-cash process easier, thereby simplifying the buying process and boosting customer satisfaction. It will also strengthen HUBS&#39; ability to address areas such as upselling, renewals and other commerce functions. Automation of subscription billing and CPQ will enable businesses to close deals faster and expedite revenue collection. A seamless purchasing process will also enhance customer retention. This will also bolster Commerce HUBS&#39; capabilities in managing clients and transaction data, enhancing enterprises&#39; visibility and decision-making.
<h2>Will This Buyout Drive HUBS&#39; Share Performance?</h2>
Customers appreciate flexibility and customization during product purchases. However, ensuring this in a legacy CPQ system, which involves several steps for product configuration, quote generation and pricing changes, is a time-consuming endeavor. This outdated billing and payment system leads to lengthy sales cycles and inefficient revenue collection. To tackle these challenges, enterprises are increasingly looking for a solution to automate key components of revenue management and enhance customer experience.
The subscription and billing management market is projected to grow at a substantial rate in the upcoming years. By integrating Cacheflow&#39;s AI-powered capabilities into Commerce Hub, HUBS is aiming to capitalize on these evolving market trends. The buyout will augment HubSpot&#39;s ability to address the complete commerce cycle for enterprises. This bodes well for long-term growth.
<h2>HUBS Stock&#39;s Price Performance</h2>
Shares of HubSpot have gained 19.2% over the past year compared with the industry&#39;s 43% growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/a5/81144.jpg?v=375653989" />
Image Source: Zacks Investment Research
<h2>HUBS&#39; Zacks Rank and Key Picks</h2>
HubSpot currently carries a Zacks Rank #3 (Hold).
Zillow Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zg#NASDAQ">ZG</a>) carries a Zacks Rank #2 (Buy) at present. In the last reported quarter, it delivered an earnings surprise of 25.81%.
ZG delivered an earnings surprise of 37.41%, on average, in the trailing four quarters. The company is witnessing solid momentum in rental revenues, driven by growth in both multi and single-family listings, which is a positive factor.
Ubiquiti Inc.&nbsp;sports a Zacks Rank of 1 at present. The company offers a comprehensive portfolio of networking products and solutions for service providers and enterprises.
Its excellent global business model, which is flexible and adaptable to evolving changes in markets, helps it to beat challenges and maximize growth. The company&#39;s effective management of its strong global network of more than 100 distributors and master resellers improved its UI&#39;s visibility for future demand and inventory management techniques.
Workday Inc.&nbsp;sports a Zacks Rank of 1 at present. In the last reported quarter, it delivered an earnings surprise of 7.36%.
WDAY is a leading provider of enterprise-level software solutions for financial management and human resource domains. The company&#39;s cloud-based platform combines finance and HR in a single system that makes the process easier for organizations to provide analytical insights and decision support.
<a href="https://www.zacks.com/stock/news/2350075/hubspot-boosts-portfolio-with-strategic-buyout-will-the-stock-gain?cid=CS-BENZ-FT-analyst_blog|company_news_tech_sector-2350075">To read this article on Zacks.com click here.</a>

Offerings

HUBS

HubSpot Boosts Portfolio With Strategic Buyout: Will the Stock Gain?

This transaction vertically integrates Bit Digital&#39;s HPC operations with an existing, fully operational and fully leased Tier 3 datacenter in a major city; provides a strong diversity of existing and prospective colocation customers; delivers a strong pipeline of expansion site opportunities and an experienced team to lead the development processes; and enables Bit Digital to offer new service offerings such as colocation and on-demand computing to complement its existing GPU offerings.
Bit Digital has acquired Enovum for a total consideration of CAD&nbsp;$62.8MM (approximately USD $46MM based on a CAD/USD exchange rate of 0.73).&nbsp;The transaction closed on&nbsp;October 11, 2024.

BTBT

Bit Digital Acquires Enovum Data Centers For Total Consideration Of Approximately $46M

Belpointe PREP Reports Hurricane Milton Inflicted No Significant Damage

Ratings for Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $252.89, a high estimate of $285.00, and a low estimate of $220.00. This current average has increased by 8.69% from the previous average price target of $232.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1728936070_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Insulet among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$269.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$250.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Matthew Taylor</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$223.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$234.00</td>
<td>$234.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Insulet. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insulet compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Insulet's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Insulet's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PODD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insulet analyst ratings.</a>
<h2>Delving into Insulet's Background</h2>
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
<h3>A Deep Dive into Insulet's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Insulet's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 23.2% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Insulet's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 38.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Insulet's ROE excels beyond industry benchmarks, reaching 21.08%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 6.85%, the company showcases effective utilization of assets.
Debt Management: Insulet's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.4, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PODD

Analyst Ratings For Insulet

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
TransCode Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) stock is sliding lower on Monday following its announcement of an upcoming <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318310991&amp;type=PDF&amp;symbol=RNAZ&amp;cdn=43164c7cc1aa0080fb04a692a6a78bd2&amp;companyName=TransCode+Therapeutics+Inc.&amp;formType=PRE+14A&amp;formDescription=Preliminary+proxy+statement+providing+notification+matters+to+be+brought+to+a+vote&amp;dateFiled=2024-05-10">annual shareholder meeting</a>.



TransCode Therapeutics has informed investors in RNAZ stock that the company will hold its annual shareholder meeting on June 13, 2024 at 9:30 a.m Eastern Time. It will hold the meeting in person and is advising shareholders to vote early through proxy.



TransCode Therapeutics notes that there are a few matters that will be voted on during the shareholder meeting. They are as follows.



<ul><li>The election of Philippe Calais, Thomas Fitzgerald, Erik Manting and Magda Marquet as members of the Board of Directors for one-year terms.</li>



<li>Approving an amendment to its 2021 Stock Option and Incentive Plan that will increase shares available for issuance by 3 million.</li>



<li>Confirming WithumSmith+Brown, PC as its independent registered public accounting firm for fiscal 2024.</li>



<li>Approval for the Board of Directors to enact a reverse stock split on a one-for-two to a one-for-forty ratio.</li>



<li>The ability to adjourn the meeting to a later date.</li>



<li>The option to cover any other business brought up before the meeting during it.</li>
</ul><h2>How This Affects RNAZ Stock</h2>



Shares of RNAZ stock are down 13.5% as of Monday morning. This is likely due to its plans for a reverse stock split. These types of announcements often cause a company&rsquo;s shares to fall as investors are wary about such actions.



Investors will find more of the lastest stock markets stories below!



We have all of the hottest stock market news for Monday! That includes what&rsquo;s happening with shares of Safe &amp; Green Development&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sgd-stock-quote/">SGD</a>)&nbsp;stock, AC Immune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/aciu-stock-quote/">ACIU</a>) stock and Tevogen Bio&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tvgn-stock-quote/">TVGN</a>) stock today. You can find out more on these matters at the following links!



<h2>More Stock Market News for Monday</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-safe-green-development-sgd-stock-down-5-today/">Why Is Safe &amp; Green Development (SGD) Stock Down 5% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-ac-immune-aciu-stock-up-45-today/">Why Is AC Immune (ACIU) Stock Up 45% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-tevogen-bio-tvgn-stock-up-54-today/">Why Is Tevogen Bio (TVGN) Stock Up 54% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-transcode-therapeutics-rnaz-stock-down-14-today/">Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?

APP, MGNX and CYCC among pre-market losers

Tevogen Bio Holdings reports Q1 results

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Tevogen Bio Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/tvgn-stock-quote/">TVGN</a>) just reported results for the first quarter of 2024.<ul><li>Tevogen Bio Holdings reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/tvgn-stock-earnings-tevogen-bio-holdings-for-q1-of-2024/">TVGN Stock Earnings: Tevogen Bio Holdings Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TVGN Stock Earnings: Tevogen Bio Holdings Reported Results for Q1 2024

Tevogen Bio Holdings (TVGN) just unveiled an update. Tevogen Bio Holdings Inc. has repurchased all outstanding shares of its Series B Preferred Sto...

Tevogen Bio's Strategic Moves Amid Nasdaq Compliance Issues

Tevogen Bio files to sell 42.5M shares, plans to offer shares and warrants for holders

Tevogen Bio Holdings Inc. reports Q2 results

Tevogen Bio gets $6M series C Preferred Stock Investment

Tevogen Bio Holdings (TVGN) has issued an announcement. Tevogen Bio Holdings Inc. has engaged in a securities purchase agreement, selling 600 share...

Tevogen Bio Holdings Announces Key Financial and Governance Moves

In this video, I review some amazing trades, one missed entry non-trade, a losing trade, and how not taking a high conviction trade can ruin them all.

A Lot Of Home Runs And One Ugly Strikeout; One New Swing Position

ACIU

AFRM

AGBA

AKYA

ALAB

AUGX

BZFD

CYCC

EAST

INVO

LAAC

LIDR

LLAP

LUNR

MGNX

MSTR

NOTV

PLTR

RNAZ

STNE

TVGN

WULF

Press Releases

Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback

Financing

Tevogen Bio's Founding CEO, Ryan Saadi, Expresses Conviction in Company's Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities

Tevogen Bio's Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health

Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

Health Care

Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation

Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation

Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024

Comments

Tevogen Bio Holdings

Actualités

Dernières nouvelles pour Tevogen Bio Holdings (NASDAQ:TVGN) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL